Data from the EudraVigilance and other drug safety databases relies on spontaneous reporting which may introduce reporting bias, underreporting adverse events and missing information
Protocols and their amendments are publicly accessible in ClinicalTrials.gov under the National Clinical Trial (NCT) identifiers NCT06659744, NCT07088718 and NCT07096063, and in the Open Science Framework (osf.io/38rw9) 43
Weight loss semaglutide is categorically excluded from formulary coverage, meaning you pay full retail or switch to compounded
[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
Studies show that patients who reach this maintenance dose typically achieve 12-15% body weight reduction over six months
This article discusses a case of a patient who developed IIH after the abrupt cessation of a GLP-1 receptor agonist with resultant rapid weight gain and discusses the potential ways that the GLP-1 receptor agonists may be useful in the treatment of IIH